Compare LEVI & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEVI | BIO |
|---|---|---|
| Founded | 1853 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 8.7B |
| IPO Year | 2019 | N/A |
| Metric | LEVI | BIO |
|---|---|---|
| Price | $21.41 | $320.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 4 |
| Target Price | $26.31 | ★ $358.50 |
| AVG Volume (30 Days) | ★ 1.7M | 179.0K |
| Earning Date | 01-28-2026 | 02-12-2026 |
| Dividend Yield | ★ 2.62% | N/A |
| EPS Growth | ★ 303.84 | N/A |
| EPS | ★ 1.51 | N/A |
| Revenue | ★ $6,589,400,000.00 | $2,557,500,000.00 |
| Revenue This Year | N/A | $1.62 |
| Revenue Next Year | $5.34 | $2.26 |
| P/E Ratio | $14.15 | ★ N/A |
| Revenue Growth | ★ 11.22 | N/A |
| 52 Week Low | $12.17 | $211.43 |
| 52 Week High | $24.82 | $373.69 |
| Indicator | LEVI | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 49.99 | 57.87 |
| Support Level | $21.21 | $313.88 |
| Resistance Level | $22.13 | $326.43 |
| Average True Range (ATR) | 0.50 | 7.67 |
| MACD | 0.03 | 2.07 |
| Stochastic Oscillator | 54.75 | 74.22 |
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver; Europe; and Asia.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.